Summary
A system for monitoring adverse drug reactions (ADR) in psychiatric inpatients was introduced in psychiatric hospitals in the FRG in May 1979. It consists of intensive drug monitoring (IDM) and a so-called “organized spontaneous reporting system” (OSR). ADR are rated separately according to impact on therapy and probability of causal relationship. With IDM all ADR (Grades I–III) are assessed in a randomly selected sample of inpatients. With OSR only ADR leading to discontinuation of the drugs in question (=ADR Grade III) are assessed. In 406 drug-treated inpatients monitored by IDM in the psychiatric hospitals of Berlin and Munich from May 1979 to Dec. 1981, ADR were observed in 60,4%. In 15% of IDM-patients ADR led to discontinuation of the drugs in question; with OSR the relative frequency of these Grade III ADR was 9,0% in 5096 patients monitored throughout the entire period. Life-threatening events were observed in 1,2% of patients undergoing IDM as well as 1.2% of those undergoing OSR. The most frequently observed ADR by IDM were sedation, extrapyramidal signs, disturbances of the autonomic nervous system and increase in transaminases, and by OSR Parkinsonism, akathisia, sedation, toxic delirium and increased transaminases. The relative frequency of Grade III ADR was similar for neuroleptics and antidepressants (5,4% and 5,3% in OSR); a very low relative frequency of ADR Grade III was found for tranquilizers and hypnotics (0,7% and 0,2%). Methodological aspects of this drug monitoring system are discussed in the light of current literature.
Similar content being viewed by others
References
Seidl LG, Thornton GF, Cluff LE (1965) Epidemiological studies of adverse drug reactions. Am J Public Health 55: 1170–75
Borda IT, Slone D, Jick H (1968) Assessment of adverse reactions within a drug surveillance program. J Am Med Assoc 205: 99–101
Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D (1970) Comprehensive drug surveillance. J Am Med. Assoc 213: 1455–1460
Ogilvie RJ, Ruedy J (1967) Adverse drug reactions during hospitalization. Can Med Assoc J 97: 1450–1457
Klein U, Gikalow I, Keller M, Hoigné R (1972) “Drug monitoring” in der Medizinischen Abteilung eines Regionalspitals. Schweiz Med Wochenschr 102: 1083–1090
Hurwitz N, Wade OL (1969) Intensive hospital monitoring of adverse reactions to drugs. Br Med J 1: 531–536
Weber E, Gundert-Remy U, Walter E, Ding R, Harenberg J, v. Kenne H, Spohr U (1978) Experiences and results of a 5-year-period of hospital drug monitoring. In: Ducrot H, Goldberg M, Hoigne R, Middleton P (eds) Computer-aid to drug therapy and to drug monitoring. IFIP, North-Holland, Amsterdam, pp 35–42
Bellantuono C, Reggi V, Tognoni G, Muscettola G (1981) Comparison of practice in hospitals and community mental health centers. In: Tognoni G, Bellantuono G, Lader M (eds) Epidemiological impact of psychotropic drugs. Elsevier North-Holland Biomedical Press, Amsterdam, pp 171–187
Ayd F (1974) Fear of side effects and denial of treatment. Direct clinical data. Rational psychopharmacotherapy and the right to treatment. Ayd Med Comm Ltd, Baltimore, pp 111–116
Swett Ch (1979) Patterns of drug use in psychiatric inpatient wards. J Clin Psychiat 16: 464–468
Rüther E, Benkert O, Eckmann F, Eckmann I, Grohmann R, Helmchen H, Hippius H, Müller-Oerlinghausen B, Poser W, Schmidt LG, Stille G, Strauß A, Überla K (1980) “Drug monitoring” in psychiatrischen Kiniken. Bericht der Arbeitsgruppe für Medikamenten-Überwachung in der Psychiatrie. Drug Res 30, 8: 1181–1183
Müller-Oerlinghausen B, Schmidt LG, Rüther E (1981) Drug monitoring in psychiatry. In: Sartorius N, Helmchen H (ed) Multicentre trials, Karger, Basel, pp 101–108
Grohmann R, Strauß A, Gehr C, Rüther E, Hippius H (1980) Zur Praxis der klinischen Therapie mit Psychopharmaka. Pharmacopsychiat 13: 1–19
Schmidt LG, Niemeyer R, Müller-Oerlinghausen B (1983) Drug prescribing pattern of a psychiatric university hospital in Germany. Pharmacopsychiat 16: 35–42
Schmidt LG, Grohmann R, Helmchen H, Langscheid-Schmidt K, Müller-Oerlinghausen B, Poser W, Rüther E (1984) Epidemiology of adverse drug reactions in psychiatric hospital. Acta Psychiatr. Scand 70: 77–89
Venulet J (1977) Methods of monitoring adverse reactions to drugs. Proc Drug Res 21: 231–292
Wardell WM, Tsianco MC, Anavekar SN, Davis HT (1979) Postmarketing surveillance of new drugs. 1. Review of objectives and methodology. J Clin Pharmacol 19: 85–94
Smith MW (1981) The case control or retrospective study in retrospect. J Clin Pharmacol 21: 269–274
Feinstein AR (1974) Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance. Clin Pharmacol Ther 16: 110–123
Finney DJ (1965) The design and logic of a monitor of drug use. J Chron Dis 18: 77–98
Slone D, Jick H, Borda I, Feinleib TC, Muench H, Lipworth L, Beleotti C, Gilman B (1966) Drug surveillance utilising nurse monitors. Lancet 2: 901–903
Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L (1976) Adverse drug reactions — a matter of opinion. Clin Pharmacol Ther 19: 489–492
Karch FE, Lasagna L (1977) Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 21: 247–254
Koch-Weser J, Sellers EM, Zacest R (1977) The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 11: 75–78
Blanc S, Leuenberger P, Berger JP, Brocke EM, Schelling JL (1979) Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther 25: 493–498
Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. 1. Background, description and instruction for use. JAMA 242: 623–632
Naranjo CA, Busto U, Sellers EM, Sander P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt EJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239–245
Tallarida RJ, Murray RB, Eiben C (1979) A scale for assessing the severity of diseases and adverse drug reactions. Clin Pharmacol Ther 25: 381–390
Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. 2. Demonstration of reproducibility and validity. J Am Med Assoc 242: 633–638
Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. 3. Result of tests among clinicians. J Am Med Assoc 242: 1991–1994
Boston Collaborative Drug Surveillance Program (1972) Adverse reactions to the tricyclic-antidepressant drugs. Lancet 1972: 529–531
Downing RW, Rickels K, Meyers F (1970) Side reactions in neurotics: A comparison of two methods of assessment. J Clin Pharmacol 10: 289–297
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grohmann, R., Hippius, H., Müller-Oerlinghausen, B. et al. Assessment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol 26, 727–734 (1984). https://doi.org/10.1007/BF00541933
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541933